Stein, E., Mims, A., Xie, Z., Mannis, G., Watts, J., Ravandi, F., Schiller, G., Ball, B., Liu, H., Altman, J., Wang, E., Cui, J. J., Zhou, J., Zimmerman, Z., Strickland, S. (2025). A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available clk inhibitor, BH-30236, in adults with R/R AML or HR-MDS. Blood. https://doi.org/10.1182/blood-2025-1655